MedaPhor, the intelligent ultrasound software and simulation company, develops advanced hi-fidelity ultrasound training simulators, artificial intelligence (AI) image analysis software and augmented reality (AR) needle guidance systems for medical practitioners.
The Ultrasound Simulation and Training division focuses on hi-fidelity ultrasound education and training through simulation. Products include the ScanTrainerTM OBGYN simulator training platform and the HeartWorksTM echocardiography simulator. Over 500 MedaPhor simulators have been sold to over 300 medical institutions around the world.
The new Ultrasound Clinical Support division focuses on developing AI algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNavTM, which uses deep-learning algorithms to automatically provide guidance, assessment and audit of obstetric scanning; and NeedleGuideTM, which aims to simplify ultrasound-guided needling with AR needle guidance and automated needle tip tracking.
Plutus PowerGen (PPG)
Rockhopper Exploration (RKH)
Rockhopper Exploration plc ("Rockhopper") is an AIM listed oil and gas exploration company based in the UK with interests in the Falkland Islands. It was established in 2004 with a strategy to invest in and undertake an offshore oil exploration programme. It was floated on AIM in August 2005.
Rockhopper holds 40% interests in production licences PL032 and PL033 and, on completion of a farm-in announced in October 2013, 24% stakes in blocks PL004a, PL004b, and PL004c. All of these blocks are operated by Premier Oil. In addition, it has a 3% interest block PL003, operated by Falkland Oil and Gas.
In August 2014 Rockhopper completed the takeover of Mediterranean Oil & Gas plc ("MOG"). Through the acquisition of MOG, Rockhopper now holds a portfolio of production, development/appraisal and exploration interests in Italy, Malta and France.
ValiRx Plc (VAL) is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering.